Nav: Home

Studies examine rheumatoid arthritis patients' prognosis

April 20, 2017

What's the long-term outlook for today's patients with early rheumatoid arthritis? A new study in Arthritis & Rheumatology that looks at patients' mortality, disease activity, and physical function over the course of 20 years reveals the importance of early treatment. Another study in the journal notes that deaths from arthritis are declining.

Investigators led by Suzanne Verstappen, PhD, of The University of Manchester in the UK, analyzed information on 602 rheumatoid arthritis patients from the Norfolk Arthritis Register who were recruited from 1990 to 1994. The team collected demographic variables and assessed disease activity (swollen/tender joint counts), disability, and mortality at various time points over 20 years.

Overall, patients had relatively low levels of disease activity from year one onwards, but disability rose to above baseline levels after seven years. This disability was moderate, however, indicating that patients experienced relatively good long-term outcomes, particularly compared with patients from earlier decades.

Patients who received treatment within six months after symptom onset had similar levels of disability over the subsequent 20 years as patients who were judged by clinicians to not require treatment. A total of 265 patients (44 percent) died, and, although not significant, there was a trend indicating that patients who received treatment within the first six months had a lower risk of death than those who did not receive treatment, after controlling for disease severity.

"This research emphasizes the importance of early treatment and the long-term benefits of early treatment," said Dr. Verstappen. "In the early 1990s, when this study started, only 30 percent of patients received early treatment, but this number has increased significantly in the last decade. It's expected that in the next 10 years, newly diagnosed patients will have a better future with respect to functional ability, less severe disease activity, and improved quality of life."

Another analysis in the journal notes that deaths attributable to rheumatoid arthritis have declined in recent years. After examining information from 31 countries, investigators found that there are substantial between-country disparities in rheumatoid arthritis mortality, but the disparities have decreased over time.

According to data from the World Health Organization, rheumatoid arthritis was registered as the underlying cause of death in 8428 cases in 2011 (0.09% of all-cause deaths), a considerable drop compared with the 9281 cases (0.12% of all-cause deaths) in 1987. The age-standardized mortality rate of rheumatoid arthritis declined by 3.0% annually from 1987 to 2011.

Population aging combined with fewer deaths from rheumatoid arthritis may lead to an increased economic burden of the disease.

"Although increased survival with rheumatoid arthritis is great news, it might lead to a greater share of our aging population having the disease and in need of health services. This needs to be accounted for in health care planning", said lead author Aliasghar Kiadaliri, PhD, of Lund University in Sweden.
-end-
Additional Information

Full Citation: "The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: results from the Norfolk Arthritis Register." James M. Gwinnutt, Deborah P.M. Symmons, Alexander J. MacGregor, Jacqueline R. Chipping, Tarnya Marshall, Mark Lunt, and Suzanne M.M. Verstappen. Arthritis & Rheumatology; Published Online: April 20, 2017 (DOI: 10.1002/art.40090).

Link to Study: http://doi.wiley.com/10.1002/art.40090

Full Citation: "Rheumatoid arthritis as underlying cause of death in 31 countries, 1987-2011: trend analysis of WHO mortality database." Aliasghar A. Kiadaliri, David T. Felson, Tuhina Neogi, and Martin Englund. Arthritis & Rheumatology; Published Online: April 20, 2017 (DOI: 10.1002/art.40091).

Link to Study: http://doi.wiley.com/10.1002/art.40091

Author Contacts: For Dr. Verstappen: Michael Addelman, of The University of Manchester's Media Relations Office, at michael.addelman@manchester.ac.uk or +44 (0) 161 275 2111.

For Dr. Kiadaliri: aliasghar.ahmad_kiadaliri@med.lu.se

About the Journal

Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (http://www.rheumatology.org) is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.

About Wiley

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

Wiley

Related Rheumatoid Arthritis Articles:

Study examines opioid use in patients with rheumatoid arthritis
A new analysis indicates that the use of opioid pain medications in older US rheumatoid arthritis patients peaked in 2010 and is now declining slightly.
Studies examine rheumatoid arthritis patients' prognosis
What's the long-term outlook for today's patients with early rheumatoid arthritis?
Obesity may influence rheumatoid arthritis blood tests
New research reveals that in women, obesity may influence blood tests used to diagnose and monitor rheumatoid arthritis.
New tool for prognosis and choice of therapy for rheumatoid arthritis
In rheumatoid arthritis, antibodies are formed that affect the inflammation in the joints.
The promise of precision medicine for rheumatoid arthritis
In a new study, a Yale-led research team identified the mechanism of a gene that raises the risk of severe rheumatoid arthritis in susceptible individuals.
Immunotherapy reduces cardiovascular risk in rheumatoid arthritis
Weight loss from bariatric surgery appears to reverse the premature aging associated with obesity, according to research presented today at Frontiers in CardioVascular Biology 2016.
Osteoarthritis just as severe as rheumatoid arthritis
Rheumatologists more likely to underestimate clinical status of their OA patients than their RA patients
Serotonin deficiency implicated in rheumatoid arthritis
For the first time, serotonin (5-hydroxytryptamine, 5-HT) has been directly implicated in the pathophysiology of rheumatoid arthritis (RA).
Link between mood, pain in rheumatoid arthritis patients
Depressive symptoms and mood in the moment may predict momentary pain among rheumatoid arthritis patients, according to Penn State researchers.
Inflammation in the mouth and joints in rheumatoid arthritis
Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Sheila Arvikar, Massachusetts General Hospital, Boston, USA, will present a study titled 'Inflammation in the Mouth and Joints in Rheumatoid Arthritis.' The IADR General Session is being held in conjunction with the 44th Annual Meeting of the American Association for Dental Research and the 39th Annual Meeting of the Canadian Association for Dental Research.

Related Rheumatoid Arthritis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...